Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SANA Stock Summary
In the News
SANA Financial details
Company Rating
Neutral
Market Cap
1.98B
Income
-281.33M
Revenue
0
Book val./share
1.46
Cash/share
1.06
Dividend
-
Dividend %
-
Employees
328
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-3.74
Forward P/E
-
PEG
-11.72
P/S
-
P/B
2.78
P/C
7.79
P/FCF
-3.53
Quick Ratio
4.03
Current Ratio
4.19
Debt / Equity
0.36
LT Debt / Equity
0.32
-
-
EPS (TTM)
-1.46
EPS next Y
-
EPS next Q
-
EPS this Y
3.55%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-9100%
-
-
-
-
SMA20
-
SMA50
50%
SMA100
125%
Inst Own
42.22%
Inst Trans
0.6%
ROA
-43%
ROE
-66%
ROC
-0.5%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.745-12.0
52W High
-31.21%
52W Low
+312.75%
RSI
44
Rel Volume
0.32
Avg Volume
2.1M
Volume
679.73K
Perf Week
-11.62%
Perf Month
-15.16%
Perf Quarter
193.77%
Perf Half Y
169.77%
-
-
-
-
Beta
1.611
-
-
Volatility
0.37%, 0.48%
Prev Close
-1.84%
Price
8.255
Change
-2.88%
SANA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.7 | -1.49 | -2.07 | -1.41 | -1.46 | |
Operating cash flow per share | -0.46 | -0.74 | -1.51 | -1.54 | -1.3 | |
Free cash flow per share | -0.6 | -0.86 | -1.69 | -1.65 | -1.41 | |
Cash per share | 0.74 | 3.55 | 3.31 | 2.25 | 1.07 | |
Book value per share | -0.76 | -2.25 | 4.38 | 2.65 | 1.48 | |
Tangible book value per share | -1.83 | -3.31 | 3.18 | 1.59 | 0.45 | |
Share holders equity per share | -0.76 | -2.25 | 4.38 | 2.65 | 1.48 | |
Interest debt per share | 0.26 | 0.38 | 0.67 | 0.49 | 0.54 | |
Market cap | 6.58B | 6.58B | 2.58B | 743.96M | 793.73M | |
Enterprise value | 6.54B | 6.24B | 2.43B | 675.45M | 760.47M | |
P/E ratio | -50.28 | -23.62 | -7.49 | -2.79 | -2.8 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -76.9 | -47.7 | -10.26 | -2.56 | -3.13 | |
PFCF ratio | -58.88 | -40.66 | -9.17 | -2.39 | -2.9 | |
P/B Ratio | -46.13 | -15.63 | 3.54 | 1.49 | 2.76 | |
PTB ratio | -46.13 | -15.63 | 3.54 | 1.49 | 2.76 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -46.97 | -21.81 | -6.82 | -2.48 | -2.58 | |
EV to operating cash flow | -76.53 | -45.23 | -9.7 | -2.33 | -3 | |
EV to free cash flow | -58.59 | -38.56 | -8.67 | -2.17 | -2.78 | |
Earnings yield | -0.02 | -0.04 | -0.13 | -0.36 | -0.36 | |
Free cash flow yield | -0.02 | -0.02 | -0.11 | -0.42 | -0.34 | |
Debt to equity | -0.34 | -0.17 | 0.15 | 0.22 | 0.36 | |
Debt to assets | 0.12 | 0.1 | 0.1 | 0.13 | 0.18 | |
Net debt to EBITDA | 0.23 | 1.19 | 0.4 | 0.25 | 0.11 | |
Current ratio | 7.28 | 12.22 | 5.62 | 3.99 | 3.31 | |
Interest coverage | 0 | 0 | 0 | 17.44 | 0 | |
Income quality | 0.65 | 0.48 | 0.71 | 1.08 | 0.9 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.48 | 0.27 | 0.18 | 0.24 | 0.35 | |
Capex to operating cash flow | 0.31 | 0.17 | 0.12 | 0.07 | 0.08 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -14.34 | -4.03 | -2.7 | -1.34 | -0.65 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 3.46 | 8.67 | 14.27 | 9.19 | 6.96 | |
ROIC | 2.89 | 1.01 | -0.36 | -0.38 | -0.68 | |
Return on tangible assets | -0.61 | -0.53 | -0.37 | -0.43 | -0.78 | |
Graham Net | -2.24 | -2.59 | 0.9 | 0.53 | -0.35 | |
Working capital | 124.43M | 353.02M | 458.87M | 332.93M | 149.03M | |
Tangible asset value | -342.36M | -621.01M | 528.68M | 299.49M | 87.68M | |
Net current asset value | -413.98M | -767.01M | 157.2M | 121.03M | -64.28M | |
Invested capital | -0.34 | -0.17 | 0.15 | 0.22 | 0.36 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 144.5K | 1.13M | 2.24M | 2.54M | 3.48M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 80.85 | 45.21 | 37.6 | 48.58 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 4.51 | 8.07 | 9.71 | 7.51 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.92 | 0.66 | -0.47 | -0.53 | -0.99 | |
Capex per share | -0.14 | -0.13 | -0.18 | -0.11 | -0.1 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.41 | -0.42 | -0.59 | 0 | -0.45 | |
Operating cash flow per share | -0.4 | -0.41 | -0.31 | -0.32 | -0.26 | |
Free cash flow per share | -0.42 | -0.43 | -0.31 | -0.33 | -0.33 | |
Cash per share | 2.23 | 1.83 | 1.69 | 1.36 | 1.06 | |
Book value per share | 2.62 | 2.24 | 1.84 | 1.86 | 1.46 | |
Tangible book value per share | 1.57 | 1.19 | 0.81 | 0.84 | 0.44 | |
Share holders equity per share | 2.62 | 2.24 | 1.84 | 1.86 | 1.46 | |
Interest debt per share | 0.56 | 0.59 | 0.59 | 0.49 | 0.53 | |
Market cap | 752.16M | 625.32M | 1.15B | 762.3M | 805.05M | |
Enterprise value | 683.65M | 579.36M | 1.09B | 690.72M | 771.8M | |
P/E ratio | -2.4 | -1.95 | -2.52 | 193.68 | -2.28 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -9.89 | -7.89 | -19.52 | -12 | -15.49 | |
PFCF ratio | -9.32 | -7.68 | -19.01 | -11.59 | -12.2 | |
P/B Ratio | 1.51 | 1.46 | 3.23 | 2.08 | 2.8 | |
PTB ratio | 1.51 | 1.46 | 3.23 | 2.08 | 2.8 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -8.36 | -6.89 | -9.35 | 297.98 | -11.13 | |
EV to operating cash flow | -8.99 | -7.31 | -18.48 | -10.87 | -14.85 | |
EV to free cash flow | -8.47 | -7.11 | -18 | -10.5 | -11.69 | |
Earnings yield | -0.1 | -0.13 | -0.1 | 0 | -0.11 | |
Free cash flow yield | -0.11 | -0.13 | -0.05 | -0.09 | -0.08 | |
Debt to equity | 0.22 | 0.27 | 0.32 | 0.26 | 0.36 | |
Debt to assets | 0.13 | 0.15 | 0.16 | 0.15 | 0.18 | |
Net debt to EBITDA | 0.84 | 0.55 | 0.52 | -30.88 | 0.48 | |
Current ratio | 3.99 | 3.6 | 3.02 | 4.19 | 3.31 | |
Interest coverage | 45.19 | 43.57 | 0 | 0 | 0 | |
Income quality | 0.95 | 0.97 | 0.52 | -64.58 | 0.59 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.24 | 0.27 | 0.28 | 0.32 | 0.35 | |
Capex to operating cash flow | 0.06 | 0.03 | 0.03 | 0.04 | 0.27 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -1.1 | -0.5 | -0.35 | -0.5 | -1.86 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 4.93 | 4.6 | 4.96 | 0.46 | 3.83 | |
ROIC | -0.11 | -0.12 | -0.19 | -0.02 | -0.16 | |
Return on tangible assets | -0.13 | -0.15 | -0.22 | 0 | -0.24 | |
Graham Net | 0.53 | 0.16 | -0.14 | 0.02 | -0.35 | |
Working capital | 332.93M | 267.13M | 226.52M | 212.88M | 149.03M | |
Tangible asset value | 299.49M | 228.44M | 155.21M | 166.03M | 87.68M | |
Net current asset value | 121.03M | 51.24M | -13.5M | 13.93M | -64.28M | |
Invested capital | 0.22 | 0.27 | 0.32 | 0.26 | 0.36 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 3.43M | 2.6M | 2.71M | 6.51M | 7.02M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 34.55 | 27.28 | 35.42 | 198.6 | 49.03 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 2.6 | 3.3 | 2.54 | 0.45 | 1.84 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.16 | -0.19 | -0.32 | 0 | -0.31 | |
Capex per share | -0.02 | -0.01 | -0.01 | -0.01 | -0.07 |
SANA Frequently Asked Questions
What is Sana Biotechnology, Inc. stock symbol ?
Sana Biotechnology, Inc. is a US stock , located in Seattle of Wa and trading under the symbol SANA
What is Sana Biotechnology, Inc. stock quote today ?
Sana Biotechnology, Inc. stock price is $8.255 today.
Is Sana Biotechnology, Inc. stock public?
Yes, Sana Biotechnology, Inc. is a publicly traded company.